Drugs /

vantictumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
vantictumab
NCI Definition [1]:
A monoclonal antibody directed against the Wnt signaling pathway with potential antineoplastic activity. Upon administration, vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This may result in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. The Wnt signaling pathway is dysregulated in many cancer cell types and appears to play a major role in CSC regulation and activity; CSC are tumor initiating cells that are able to self-renew and are responsible for tumor growth and resistance.

Clinical Trials

View Clinical Trials for vantictumab

Vantictumab has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating vantictumab, 1 is phase 1 (0 open).

HER2 Deficient Expression and HER2 Negative are the most frequent biomarker inclusion criteria for vantictumab clinical trials.

Breast carcinoma is the most common disease being investigated in vantictumab clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vantictumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vantictumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
omp-18r5, anti-wnt signaling pathway monoclonal antibody omp-18r5, anti-wnt signaling pathway monoclonal antibody omp-18r5
Drug Categories [2]:
FZD inhibitors, Therapeutic antibodies
Drug Target(s) [2]:
FZD1, FZD2, FZD5, FZD7, FZD8
NCIT ID [1]:
C96799

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.